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Abstract
Background: The main challenge for systemic radiation therapy using radiopharmaceuticals (SRT) is to optimise the
dose delivered to the tumour, while minimising normal tissue irradiation. Dosimetry could help to increase therapy
response and decrease toxicity after SRT by individual treatment planning. Peptide receptor radionuclide therapy
(PRRT) is an accepted SRT treatment option for irresectable and metastatic neuroendocrine tumours (NET).
However, dosimetry in PRRT is not routinely performed, mainly due to the lack of evidence in literature and clinical
implementation difficulties. The goal of this review is to provide insight in dosimetry methods and requirements
and to present an overview of clinical aspects of dosimetry in PRRT for NET.
Methods: A PubMed query including the search criteria dosimetry, radiation dose, peptide receptor radionuclide
therapy, and radionuclide therapy was performed. Articles were selected based on title and abstract, and description of
dosimetric approach.
Results: A total of 288 original articles were included. The most important dosimetry methods, their main advantages
and limitations, and implications in the clinical setting are discussed. An overview of dosimetry in clinical
studies regarding PRRT treatment for NET is provided.
Conclusion: Clinical dosimetry in PRRT is feasible and can result in improved treatment outcomes. Current
clinical dosimetry studies focus on safety and apply non-voxel-based dosimetry methods. Personalised treatment using
sophisticated dosimetry methods to assess tumour and normal tissue uptake in clinical trials is the next step towards
routine dosimetry in PRRT for NET.
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Background
Ionising radiation is already effectively used to treat can-
cer for over a century. In this respect, several sources of
radiation with different features and clinical applications
are available. External beam radiation therapy (EBRT)
delivers high-energy ionising radiation from outside the
body, whereas brachytherapy involves sealed sources
internally placed in proximity to the target [1, 2]. This
manuscript focuses on the third type of therapeutic radi-
ation: systemic radiation therapy (SRT), also known as
radionuclide therapy. Like the localised EBRT and brachy-
therapy, SRT results in a palliative or curative effect by in-
gestion or systemic administration of a molecular
complex containing a β−- or α-emitting isotope [2, 3]. Al-
though SRT has been used for decades, it has gone
through a revival with the introduction of targeted radi-
olabelled antibodies and small molecules. Examples are
somatostatin analogues directed towards the somatostatin
receptor and ligands to target the prostate-specific
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membrane antigen (PSMA) to treat neuroendocrine
tumours (NET) and prostate cancer, respectively. This
type of SRT is often referred to as peptide receptor radio-
nuclide therapy (PRRT) for NET and peptide radionuclide
ligand therapy (PRLT) for prostate cancer [4, 5]. The wide-
spread introduction of PRRT for NET in the USA and in
Europe was stimulated by the completion of the phase III
NETTER-1 study. In this study, safety and effectiveness of
Lutetium-177 (177Lu) DOTATATE was evaluated in meta-
static midgut NET patients and resulted in market regis-
tration [6]. A meta-analysis by Kim et al. shows that the
average disease control rate after treatment with PRRT is
82%. However, response rates are lower: 18–44% based on
RECIST criteria and 7–37% based on SWOG criteria [7].
The key to any type of radiation therapy is to ensure
sufficient absorbed dose into tumour lesions, while mini-
mising the burden to healthy tissues. Treatment plan-
ning and dose verification using dedicated software to
optimise the balance between tumour control probability
(TCP) and normal tissue complication probability
(NTCP) is considered standard of care in the field of ra-
diation therapy [8]. Still, when applying SRT, most cen-
tres employ a ‘one-size-fits-all’ approach for the amount
of radioactivity administered similar to chemotherapeu-
tic regimes, rather than calculating individualised in-
ternal dose estimates [9–11]. Dosimetry in SRT may
refer to either the estimation of radioactivity that needs
to be administered to achieve a desired absorbed dose
(i.e. planning or pre-treatment dosimetry) or estimation
of the absorbed radiation dose after administration of
the radiopharmaceutical (i.e. verification or
post-treatment dosimetry) [12]. The absorbed dose can be
estimated if information on patient-based radiopharmaceu-
tical kinetics, biodistribution, isotope characteristics, ana-
tomical geometry and tissue densities are present [2, 12]. In
this respect, TCP and NTCP values used in EBRT cannot
be directly applied to SRT, as the absorbed dose in both
therapies does not result in the same cell killing effect.
EBRT delivers high dose rates in a controlled setting using
an external irradiation source, whereas in SRT, radioactive
sources delivers a low and continuously decreasing dose
rate for longer time [13, 14]. In a series of recent published
editorials, experts in the field of nuclear medicine, physics
and dosimetry provided their vision on the usability of indi-
vidual dosimetry for SRT [11, 15, 16]. Proponents state that
the amount of administered radioactivity should be ‘as high
as reasonably possible’ to achieve an optimal treatment out-
come. This requires, however, personalised analysis as inter-
patient pharmacokinetic variations are large. Furthermore,
they suggest that dosimetry-based optimisation should be
added to the registration, in addition to fixed treatment
schemes, to allow for clinical dosimetry [11, 15]. Opponents
state that dosimetry has a role in radiopharmaceutical de-
velopment and safety, but its clinical use is not
evidence-based. They emphasise caution when transferring
from the well-established and safe empirical dosage
schemes towards the complex, time-consuming, and
non-standardised dosimetry approaches [16]. Regardless of
this ongoing discussion, the 2013/59/Euratom statement of
the European Union stipulates that radiotherapeutic proce-
dures should be individually planned and verified [17].
This literature review discusses the main dosimetry
methodologies for PRRT in NET, their drawbacks and
appropriate use followed by a structured overview of
clinical applications. Additionally, imaging quantifica-
tion, kinetic modelling and the biologically effective dose
are briefly touched upon.
Review
Search strategy
The search strategy was designed to identify published
peer reviewed articles that cover dosimetry in a clinical or
technical research setting concerning PRRT for NET.
Studies published between July 2006 and July 2017 were
included. A PubMed search was performed using the fol-
lowing terms: “PRRT”[All Fields] OR “nuclear therapy”[All
Fields] OR “radionuclide therapy”[All Fields]) AND (“dosi-
metry”[All Fields] OR “radiation dose”[All Fields]). Add-
itional filter included the English language and letters,
commentaries, editorials, case reports, reviews and pre-
clinical studies were excluded.
Selection for full-text review
Articles identified based on the search strategy were sub-
divided into two groups based on title and abstract: (1)
technical description of dosimetry or (2) clinical dosimetry
in PRRT for NET. Technical articles should at least
describe the imaging methodology, data type (digital simu-
lation, phantom or patient data), isotope and dosimetry
methodology. Clinical articles should focus on PRRT and
had to describe the radiopharmaceutical, administered
radioactivity, patient population, dosimetry methodology,
imaging approach and absorbed dose estimates.
Results
In total, 288 unique articles were identified from the
structured search, including 181 original articles, 38 pre-
clinical articles and 69 reviews/guidelines/recommenda-
tions. Initial selection based on title and abstract
excluded 195 articles; after analysis of full-text articles,
only 32 out of 288 articles fulfilled the selection criteria
(14 technical, 18 clinical). The detailed selection work-
flow is shown in Fig. 1, and a summary of the included
articles is provided in the Additional file 1: Tables S1
and S2. In the following four consecutive sections,
Monte Carlo simulation, the Medical Internal Radiation
Dose (MIRD) formalism and S values, dose kernels and
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local energy deposition are discussed. An overview of all
methods is provided in Table 1.
Method 1: Monte Carlo simulations of radiation transport
Monte Carlo (MC) simulation is based on an iterative
statistical process to estimate random pathways and in-
teractions of particles in three dimensions, allowing for
voxel-level absorbed dose estimations [18]. Numerous
input parameters are required for an accurate simula-
tion, including scattering and absorption behaviour,
medium characteristics and the number of simulated
primary particles. In general, MC simulations are quite
extensive taking tissue penetration depth, energy loss,
bremsstrahlung photons and cross-fire dose into account
[19, 20]. The cross-fire dose refers to irradiation of a
structure by its surroundings and is especially relevant
for isotopes with γ-emission due to the longer path
length through tissue compared to β−- and α-particles or
auger electrons. Voxel-based methods that incorporate
cross-fire dose will result in improved dose estimations
[19]. Different MC simulator toolkits are nowadays avail-
able (see Additional file 1).
The main advantages of MC simulations are the cap-
ability to account for an inhomogeneous radioactivity
distribution, induction of secondary particles (often
γ-radiation), transitions between tissue types, and
patient-specific organ and lesion geometries [21, 22].
Modern quantitative imaging techniques (PET/CT and
SPECT/CT) are as input for MC simulations and pro-
vide information on anatomical geometry, tissue dens-
ities, heterogeneities and (non-uniform) distribution
patterns. To date, full MC simulations are not recom-
mended for routine clinical use due to complex calcula-
tions and relative long computational times (roughly
3 h for ~ 10 million simulations) [23–25]. In most arti-
cles, MC simulations in PRRT are used to validate new
faster algorithms for specific assumptions on activity
distributions, absorption, cross-fire, and tissue transi-
tions [19, 20, 22, 24, 25].
Method 2: MIRD formalism and S values
The MIRD formalism, as developed by the Medical
Internal Radiation Dose (MIRD) committee of the Soci-
ety of Nuclear Medicine (SNM), was originally designed
Table 1 Overview of dosimetry methods
Method Assumptions Advances Drawbacks Clinical application
Monte
Carlo simulation
Simulation of certain number of
particles. Manual particle energy
cut-off values





Not applicable for clinical
routine. Calculation of S
values and dose kernels
S values Homogeneous radioactivity
distribution in tissue
Fast, easy, commonly used
and generally accepted
Based on reference phantoms,
mean absorbed dose per tumour
or organ
Organs and lesions without
superimposition. Toxicity
studies
Dose kernels Homogeneous radioactivity
distribution within one voxel,
infinite homogeneous tissue
density
DVH and isodose lines,
patient-specific
Calculated for each radionuclide,
not tissue specific. Mean
absorbed dose per voxel
Patient-specific voxel-based




All energy is absorbed in the
source voxel
Fast Not suitable for photons Primarily for β−- and α-
emitters
Fig. 1 Selection workflow of the search query
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to estimate average radiation doses to patients as re-
ceived by radiopharmaceuticals [26]. The system
provides a framework to assess mean absorbed doses to
organs, tissues, voxels and cellular compartments [27].
The formalism presumes deposition of energy from source
volume s in target volume t described by (t← s) [28–30].
Quantitative imaging at multiple time points are required
to create the time-activity curve, from which the cumula-
tive radioactivity (~A) in a volume of interest is calculated.
The MIRD formalism can be adopted using S values
(mGy MBq− 1 s− 1), which describe the mean absorbed
dose in the target volume per unit cumulative radioactiv-
ity in the source. S values have been determined for vari-
ous isotopes using MC simulations [29, 31, 32]. The
source-to-target distance, tissue density, target mass and
the radionuclide emission spectrum impact the S value.
Nowadays, S values are available for specific tissues and
radiopharmaceuticals in software packages [33].
Homogeneous distribution of radioactivity within or-
gans and standardised organ mass are assumed when
using S values as described in MIRD pamphlet no. 5
(1975) and no. 11 (1969) [29, 31]. Traditionally, simple
mathematical humanoid models, including standardised
organs with fixed dimensions and spheres of different
volumes to represent tumours, were used for dosimetry
analysis while assuming infinite homogeneous media with
soft tissue density [31]. The latest MIRD/ICRP (Inter-
national Commission on Radiological Protection)
voxel-based anthropomorphic phantoms are specified for
male, female and children of different ages [28]. Although
patient-specific organ masses can be derived from diag-
nostic imaging, adjustments for position, tissue inhomo-
geneity and shape of organs are not yet feasible [22, 34].
S value dosimetry is accessible for clinical use due to
relative simple, quick algorithms that only requisite
sequential 2D imaging to estimate activity distributions
and the use of average organ characteristics [30]. This
technique has become the standard dosimetry method
for pharmaceutical studies, despite the previous men-
tioned assumptions [35–38]. Tumour dosimetry is pos-
sible, although cross-fire dose is not taken into
consideration and tumour lesions are assumed to be
spherical [39]. In recent literature, S values are applied
in treatment safety monitoring [13, 35, 40, 41]. Further-
more, dosimetric analysis using S values is often used as
a reference for new dosimetry methodologies [42–44].
Method 3: dose kernels for voxel dosimetry
Quantitative 3D imaging techniques like PET/CT and
SPECT/CT visualise non-uniformities within organs and
tumours on a voxel-level. MIRD pamphlet no. 17 (1999)
provides voxel-based dosimetry in analogy with the
MIRD formalism using voxel S values (VSV). VSV are
specified for specific isotopes and voxel dimensions, cal-
culated using MC simulations [22, 45]. Each voxel is
considered an individual uniform source and neighbour-
ing voxels as uniform targets [24, 46]. Mean absorbed
dose calculations per voxel are performed using a dose
kernel matrix (mGy MBq− 1 s− 1), resulting in a
voxel-by-voxel dose map [47]. Dose estimates may differ
depending on the MC code. However, variances are
often within a few percent and are not considered rele-
vant in a clinical setting [21, 34, 44].
Advantages of dose kernel dosimetry are the ability of
handling inhomogeneous radioactivity distributions at
organ or tumour level [24]. Furthermore, 3D dose distri-
butions enable visualisation of isodose lines and
dose-volume histograms (DVHs) for radiobiological
assessment, as shown in Fig. 2 [44, 46]. This approach is
quickly gaining popularity in centres that have sufficient
SPECT/CT or PET/CT capacity and that want to per-
form patient-centred dosimetry, as the calculation time
is about 10 s per case [24]. Still, it has to be stated that
full MC simulations should be used when different tissue
densities (other than soft tissue) or inter-voxel heteroge-
neities are deemed relevant [19, 22, 34].
In literature, dose kernel research focuses on density
corrections, methods to speed up the calculation and
comparison of different kernels [24, 48, 49]. In addition,
in-house software tools with VSV are widely developed
[19, 25, 43, 50].
Method 4: local energy deposition
In addition to the three main pillars of dosimetry in nu-
clear medicine therapy, local energy deposition method
for dosimetry calculations is applied. Here, all energy is
assumed absorbed in the voxel of origin. This theory
holds true for certain α- and β-particles or auger elec-
trons, but does not apply for γ-emissions or secondary
photons due to the longer penetration depth. However,
if one is primarily interested in assessing certain parts of
the radionuclide emission spectrum, then this method is
fairly accurate for a quick analysis like in toxicity studies
[19, 51, 52]. Other methods should be considered for ra-
dionuclides with high γ-yield, and therefore, a high con-
tribution of cross-fire dose [19, 20]. This γ-irradiation
cross-fire effect between tumour and organ or between
organs is considered marginal in PRRT [53, 54]. Yet,
cross-fire of β−-particles due to internalisation of the
labelled peptides between cells is significant [55].
Clinical dosimetry in PRRT for NET
Already in 2011, the EANM Dosimetry Committee pub-
lished a ‘good practice’ document on dosimetry report-
ing, stimulating structured reporting of scientific results
with specific attention for instrumentation and protocols
[56]. Details concerning (gamma) camera type, including
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collimator, number of heads and crystal thickness should
be noted. Furthermore, acquisition settings, camera cali-
bration procedures, and image processing and analysis
should be described in detail when performing dosim-
etry. The pharmacokinetic section should include the
number of time points, type of time-activity curve fitting
and interpolation. Finally, the source of S values, tumour
dosimetry methodology and origin of organ mass need
to addressed. Surprisingly, most clinical dosimetry arti-
cles as discussed in this review did not provide all details
on image acquisition and kinetic modelling.
Out of the 18 selected clinical articles on PRRT in
NET, 11 articles used planar gamma imaging, 4 articles
used SPECT/CT and 3 articles combined both tech-
niques (see Additional file 1). Sandström et al. recom-
mended the use of SPECT/CT for tumour dosimetry,
since this modality enables improved quantification
accuracy compared to planar gamma imaging [57].
Variations concerning the number of time points for
kinetic modelling were observed, as three up to seven
time points were described. The importance of sequen-
tial imaging, and especially inclusion of late time points
(> 48 h post-injection for small molecules as used in
PRRT), is indicated by multiple studies. The addition of
late time points may affect the cumulative radioactivity
with ~ 5% [52, 53, 58–60]. Figure 3 visualises the effect
on time-activity curve fitting while omitting an early or
late time point. The MIRD formalism with S values from
the OLINDA/EXM software package or tabulated dose
factors (DF) acquired from the RADAR website were
applied in all but two articles. One article performed the
local energy deposition method, while the other one
applied VSV.
Most of the included clinical studies were designed
for safety monitoring; 12 articles focussed on the kid-
ney and 4 articles on bone marrow (BM) toxicity.
Regarding kidney toxicity, multiple publications rec-
ommended individualised kidney dosimetry due to the
high interpatient variability of absorbed doses [13, 52,
54, 61]. Dose-response relations were presented in
various papers, for example, Schuchardt et al. de-
scribed the association between mean absorbed doses
and kidney toxicity [41]. An individualised treatment
schedule for PRRT with standardised kidney absorbed
doses of 23 Gy was proposed by Del Prete et al.,
which resulted in increased tumour doses while limit-
ing renal toxicity in simulated personalised treatment
schemes. Hence, a personalised PRRT schema based
on tumour dosimetry would have led to higher mean
absorbed doses to the kidney. This method is cur-
rently evaluated in a prospective clinical trial [40].
Most studies adopted kidney absorbed dose thresholds
between 23 and 27 Gy [9, 36, 40, 62]. Bergsma et al.
suggested to increase the kidney maximum absorbed
dose up to 28 Gy [36]. This is supported by the fact
that half of the patients do not reach 23 Gy after
Fig. 2 Example of kidney dosimetry after PRRT in PLANET® Dose. Isodose lines superimposed on anatomical images provide a detailed view
(upper left), whereas the summary table (lower left) and dose-volume histogram (lower right) enable a quick assessment. Courtesy of DOSIsoft SA
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4 cycles of 7.4 GBq 177Lu-DOTATATE [57]. Individ-
ual dosimetry would have enabled additional cycles of
PRRT in these patients. Moreover, dosimetry was
used to evaluate the kidney dose delivered by differ-
ent 177Lu-labelled peptides [63].
In conjunction to kidney dosimetry, individualised
dosimetry to assess BM toxicity is indicated and a dose
limit of 2 Gy is accepted [58, 64]. BM dosimetry can be
performed using both imaging and non-imaging ap-
proaches [65]. Sequential blood samples are often used
to estimate the self-dose to the BM using blood kinetics
[10, 58, 64, 65]. In most patients, self-dose is the most
dominant source of BM irradiation [9]. However, estima-
tion of the cross-fire effect from large organs (mainly
the kidney, liver and spleen) and bone metastases
require quantitative imaging [58]. Whole-body scintig-
raphy is essential in this respect, as the field-of-view of
SPECT/CT is limited, and the activity in the remaining
body cannot be estimated [54]. Alternatively, urine sam-
ples can be used to estimate the activity in the remain-
der of the body [58]. Yet, collecting urine and blood
samples is labour intensive for both the patient and hos-
pital employees. Imaging is often performed using three
to four time points, where blood sampling five up to
eight samples was described [9, 58, 64]. Clinical BM dos-
imetry studies were based on imaging, urine and blood
sampling data. In addition, a novel method using only
planar imaging to estimate the BM dose without blood
sampling is available [62].
Tumour dosimetry was described in nine clinical
studies, and an association between absorbed tumour
dose and therapy outcome was observed in two stud-
ies [53, 59]. Simulated personalised PRRT based on
the absorbed dose by the kidney resulted in a
1.47-fold higher tumour dose, what could lead to in-
creased therapy response in a clinical situation [40].
Furthermore, the relation between uptake on diagnos-
tic imaging and dosimetry was studied [66].
Conclusions
This review provides a structured overview of modern
dosimetry methods in PRRT and their current clinical
applications, potentials and limitations in NET treat-
ment. In the last decade, many steps have been made
towards personalised PRRT in NET using dosimetry.
The incentive to perform dosimetry to optimise PRRT
for individual patients is of importance, as limited data
about maximum tolerable dose to normal tissue and
optimal tumour dose is still known [67]. For instance,
three phase II studies did not reach the maximum toler-
ated administered activity, while reporting response rates
between 7 and 54% [68–70]. Though we are far from
achieving high response rates, most patients treated with
PRRT are assumed palliative patients, so optimising
Fig. 3 Example of time-activity curve fitting. Optimal curve fitting using all five time points is represented by the solid black line. The dash-dot
line demonstrates what happens if an early time point is not performed; the maximum activity is underestimated. An overestimation of activity in
the tail of the curve could occur when a late time point is omitted (dotted line). Adapted from [37]
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treatment implicates extending a patient’s life in relative
good health. The individual optimal number of cycles
and administered activity can be determined using
tumour and normal tissue dosimetry. On the other hand,
population data can be used to determine for example
the average maximum absorbed dose to the kidney and
the influence of fractionated treatment [71]. Neverthe-
less, several hurdles need to be overcome prior to rou-
tine clinical implementation.
Dosimetry protocols
The included clinical articles implemented various
dosimetry protocols. Most studies applied S value
based dosimetry from difference sources, despite rec-
ommendations to use voxel-based approaches [57,
72]. In our opinion, dose kernels are the most appro-
priate method for dosimetry in PRRT. The main rea-
son is that heterogeneous organ and tumour uptake
can be taken into consideration, yet the method is
more practicable compared to the complicated MC
simulations [24, 46]. Furthermore, the number of time
points for post-therapy imaging was diverse. Current
guidelines do not propose specific time points, but
address the essence of dispersed post-therapy imaging
in case of slow radiopharmaceutical washout [73].
Two to three time points in both the uptake and ex-
cretion phase are recommended [30]. Nevertheless,
for wide clinical implementation four up to six time
points are unsuitable for clinical departments as it is
time consuming. Recent research has focussed on
optimising the number of time points, for example by
only using one late time point [74]. Maaβ et al. ap-
plied pharmacokinetic models based on individual and
population information to estimate kidney and
tumour uptake with different sampling schedules [75].
For the kidneys, the use of only the 4 h and 2 days
time point allowed for sufficient time-integrated activ-
ities estimates. This approach was not appropriate for
tumours, as the uptake variability between patients is
large, so for tumour dosimetry, one has to stick to at
least two early and two late time points. Finally, the
importance of late time point imaging to estimate the
tail of the curve was pointed out by multiple clinical
papers [52, 53, 58–60].
In addition, it is essential to provide a complete over-
view of the applied methodology, as is pointed out by
the EANM [56], in order to compare and share know-
ledge. For dosimetry opponents, the lack of
well-designed studies to demonstrate the value of indi-
vidual dose planning and verification is the main reason
not to deviate from empirical posology schemes [16].
Nonetheless, the joint IAEA, EANM and SNMMI prac-
tical guideline on PRRT for NET states that
patient-specific dosimetry can provide valuable
information and dosimetry could contribute to PRRT
optimization [38]. Therefore, it is essential that radio-
pharmaceutical companies and regulatory agencies
allow for dosimetry-based individual treatment sched-
ules and not only fixed administrations [15].
Safety considerations
In research, most clinical studies focus on therapy safety
while using fixed activities and intervals between cycles.
This results in a lack of clinical evidence for
patient-based dosimetry. A number of studies observed
patient-specific dose-effect relationships concerning
tumour lesions and kidney or bone marrow dose, which
could result in increased response and decreased toxicity
rates [35, 59, 61, 76]. Dosimetry can be used to assess in-
dividual risks for renal toxicity, when combined with 3D
imaging and patient-specific volumes and masses [72,
76]. In most clinical evaluations, the maximum kidney
dose is fixed to 23 Gy, which is the 5% probability of
nephrotoxicity 5 years after irradiation as used in EBRT
[53, 77]. However, this threshold might not be appropri-
ate for PRRT [36]. The recent prospective study of
Garske-Román et al. shows a response rate of 30.9%
based on RECIST criteria in patients who have received
23 Gy to the kidney [78]. In this group, only one patient
showed grade 4 nephrotoxicity 3 years after PRRT and
no grade 3 toxicity was observed. This fact supports the
hypothesis that currently, most patients are undertreated
if the number of cycles and amount of administered
radioactivity is based on the 23 Gy absorbed dose by the
kidney. The biologically effective dose (BED) can be of
interest, as it indicates the absorbed dose with the same
biological effect independent from the irradiation source.
Adjustments for BED calculations for PRRT are sug-
gested, due to the low dose rates and inhomogeneous ir-
radiation during PRRT compared to EBRT [72].
Differences in BED and treatment schedules are ex-
plored for PRRT using both 90Yttrium (90Y) and 177Lu
[79]. The BED can be determined in vitro using the
linear-quadratic model, which describes cell survival
after direct DNA damage. Indirect damage due to the
bystander effect could occur due to the long irradiation
times and relatively low dose rates in PRRT. Irradiated
cells may induce radiation effects in surrounding cells by
cell-to-cell contact and the abscopal effect. This
bystander effect implies the release of mediators to
induce oxidative stress in neighbouring cells [80]. Fur-
ther research on radiobiology and clinical dosimetry
studies, preferably by randomised clinical trials, should
be combined to optimise PRRT [15, 16].
Technical imaging considerations
Clinical dosimetry is challenging due to the balance be-
tween clinical and technical requirements. Sequential
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post-therapy 3D imaging and subsequent image process-
ing to provide voxel-based dosimetry is time-consuming
and is, for now, reserved to a limited number of specia-
lised centres. Whereas planar gamma images suffer
from superimposition, what complicates accurate de-
termination of radioactivity concentrations. The
addition of at least one SPECT acquisition can con-
tribute to quantification optimisation, while providing
a time-efficient imaging protocol [39, 81]. When se-
quential imaging is limited to planar gamma imaging
in clinical routine, the conjugate-view method with
one additional SPECT/CT (hybrid approach) will in-
crease accuracy of delineation and quantification [81].
Still, both planar and SPECT imaging suffer from the
γ-imaging drawbacks such as limited spatial resolution
due to scattered photons, collimator septal penetra-
tion by high-energy photons, attenuation, and statis-
tical noise in low count rates [30, 82]. A comparison
between quantitative imaging based on only planar
imaging, the hybrid approach and multi SPECT/CT
imaging showed a significant difference between all
three methods [83]. Multi whole-body planar and hy-
brid dosimetry resulted in an overestimation of the
mean absorbed kidney dose compared to multi
SPECT/CT of 1.6 and 1.2 times, respectively. From a
quantitative perspective, it is recommended to per-
form at least one SPECT/CT acquisition to improve
quantification accuracy, provided that the calibration
factor is determined according to guidelines [82].
Techniques like CT-based attenuation correction are
strongly advised in SPECT/CT and PET/CT to im-
prove quantification. Likewise, scatter correction and
iterative reconstruction techniques may further im-
prove image quality and quantitative assessment [84].
A harmonisation initiative as is provided by the
EANM (EANM Research Ltd., EARL) could aid in
improvements of multicentre quantitative gamma im-
aging [85]. A Dutch quantitative SPECT initiative
already performed a multicentre analysis for 99mTech-
netium studies [86].
Image processing using relatively small volumes of
interest (VOI) of ~ 4 ml could decrease the time in
preparation for dosimetry in solid organs. Manual
whole-organ segmentation is time-intensive, and kidney
volume determined by thresholding is unstable and often
changes over time. Studies have shown that this small
VOI method results in less than 5–10% difference in
absorbed dose compared to segmentation based on ana-
tomical information or thresholding [40, 54, 57]. As
regards to tumour dosimetry, we suggest to segment the
full lesion instead of small VOI segmentation. Tumours
show more often heterogeneous uptake compared to
healthy tissues. Small VOI segmentation might therefore
over- or underestimates the total lesion dose.
Dosimetry software considerations
Many dosimetry methods as described in the technical
articles use in-house developed algorithms, limiting the
translation of results to other centres. Within the EU,
software tools are considered medical devices when they
are used for clinical decision-making, through which
FDA/CE-approval is a prerequisite for implementation.
At the time of writing, only a handful of FDA/CE-ap-
proved systems are commercially available. OLINDA/
EXM® v1.0 developed by the RADAR-group was one of
the first registered tools and has recently been commer-
cialised by Hermes Medical Solutions (OLINDA/EXM®
v2.0, Stockholm, Sweden) [33, 87]. Other just recently
CE-marked commercial systems are PLANET® Dose
(DOSIsoft, Chachan, France) and Simplicit90Y™ (Mirada
Medical Ltd., Oxford, UK). All tools initially focused on
either 2D or 3D dose planning or verification, but are
gradually providing 2D/3D dosimetry solutions for PRRT
to enable a hybrid dosimetry approach. Up to now, no
studies are published comparing absorbed dose out-
comes of these systems.
Proposal for a clinical dosimetry workflow in PRRT
Any dosimetry workflow for PRRT in NET depends on a
few critical steps, see Fig. 4. Sequential imaging is essen-
tial to create a proper time-activity curve and determine
the cumulative activity in a volume of interest [75, 88].
We recommend to use three late time points, with the
latest time point at least later than two effective
half-lives of the radiopharmaceutical, to accurately fit
the tail of the time-activity curve [30].
In our opinion, the hybrid 2D/3D approach provides
sufficient quantification accuracy while patients do not
have to go through sequential long SPECT/CT acquisi-
tions. Multiple authors share this point of view [81, 83].
Still, one has to take in mind that quantitative SPECT
errors between 5 and 18% are noted in phantom experi-
ments [82, 89].
In our current clinical experience, adjustments of the
administered activity in PRRT are based on haemato-
logical assessment. In case of decreased blood parame-
ters, the administered activity will be reduced from the
standard 7.4 GBq to either 3.7 or 5.5 GBq. Based on the
aforementioned uncertainties in dose estimations and
practical reasons; we feel that adjustments to the admin-
istered activity based on dosimetry should be adapted in
steps of ~ 1 GBq.
Optimisation of tumour control and normal tissue
toxicity is of main concern in individual dosimetry for
PRRT, thus the dosimetry methodology should meet that
demand. MC simulations should be avoided in standard
clinical setting due to the inherent complexity. S values
are highly accessible since 3D imaging is not a requisite;
however, the method is not designed for inhomogeneous
Huizing et al. EJNMMI Research  (2018) 8:89 Page 8 of 11
activity distributions [31]. Dose kernel approaches are
nowadays available to handle heterogeneous radioactivity
distributions at voxel-level for individual tumour or nor-
mal tissue dose planning or verification. An advantage of
voxel-based methods is the ability to calculate DVHs
and show isodose lines, which can assist in treatment
optimisation [24]. Post-therapy visualisation of the actual
delivered tumour dose allows for clinical correlation
with the local tumour response, even in a multicentre
setting. This approach is expected to contribute to PRRT
prescription of administered activity, as tumour-type
based response and expected toxicities can be tailored.
Finally, large multicentre trials are essential to take big
steps in data collection, improvement of quantitative im-
aging across all centres performing PRRT and harmon-
isation of dosimetry methodologies. The need for
randomised controlled clinical trials is acknowledged by
both physicians and physicists [11, 14]. A certain trial
requires well-organised harmonised training to perform
quantitative imaging, time-activity curve fitting and dos-
imetry calculations from a technical perspective. Proper
trials could further aid in optimisation from a radiobio-
logical point of view, as current literature contains a
large variety of dosimetry methodologies [90]. If a large
consortium for dosimetry in PRRT can be established,
the future will be bright for NET-patients.
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